2. Anti-infection
  3. Virus Protease
  4. Glycyrrhizic acid

Glycyrrhizic acid  (Synonyms: Glycyrrhizin)

Cat. No.: HY-N0184 Purity: 99.65%
COA Handling Instructions

Molarity Calculator

Glycyrrhizic acid is a triterpenoid saponinl, acting as a direct HMGB1 antagonist, with anti-tumor, anti-diabetic activities.

For research use only. We do not sell to patients.

Glycyrrhizic acid Chemical Structure

Glycyrrhizic acid Chemical Structure

CAS No. : 1405-86-3

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 55 In-stock
Solution
10 mM * 1 mL in DMSO USD 55 In-stock
Solid
50 mg USD 50 In-stock
100 mg USD 80 In-stock
500 mg USD 240 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 23 publication(s) in Google Scholar

Other Forms of Glycyrrhizic acid:

Glycyrrhizic acid Related Antibodies

Top Publications Citing Use of Products

    Glycyrrhizic acid purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2020 Jun;53(6):e12829.  [Abstract]

    Protein levels of pro-caspase-1 + p10 + p12, GADMD, IL-1β, IL-18 and NLRP3 are detected by Western blotting. Glycyrrhizin inhibits pyroptosis in TNF-α-induced M1 macrophages.

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Glycyrrhizic acid is a triterpenoid saponinl, acting as a direct HMGB1 antagonist, with anti-tumor, anti-diabetic activities.

    In Vitro

    Glycyrrhizic acid shows a series of anti-cancer-related pharmacological activities, such as broad-spectrum anti-cancer ability, resistance to the tissue toxicity caused by chemotherapy and radiation, drug absorption enhancing effects and anti-multidrug resistance (MDR) mechanisms, as a carrier material in drug delivery systems[1].
    In intestinal NCI-H716 cells that secretes GLP-1, Glycyrrhizic acid promotes GLP-1 secretion with a marked elevation of calcium levels. Glycyrrhizic acid can enhance GLP-1 secretion through TGR5 activation[2].
    Glycyrrhizic acid can form a stable transparent low-molecular-weight hydrogels (LMWHs) at 37°C in physiological phosphate buffered saline (PBS) with nanoclusters as the microstructures[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Glycyrrhizic acid Related Antibodies
    In Vivo

    In type 1-like diabetic rats induced by streptozotocin (STZ-treated rats), Glycyrrhizic acid increases the level of plasma GLP-1, which is blocked by triamterene at a dose sufficient to inhibit Takeda G-protein-coupled receptor 5 (TGR5)[1].
    Glycyrrhizic acid (Glycyrrhizic acid; 50 mg/kg, i.p.) significantly decreases the levels of TgAb, HMGB1, TNF-α, IL-6, IL-1β in mice[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    822.93

    Formula

    C42H62O16
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    C[C@]12[C@@](C(C=C3[C@]2(CC[C@]4(C)[C@@]3([H])C[C@](C(O)=O)(C)CC4)C)=O)([H])[C@@]5([C@@](C(C)([C@@H](O[C@]6([H])[C@@H]([C@H]([C@H](O)[C@@H](C(O)=O)O6)O)O[C@]7([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]7O)C(O)=O)CC5)C)([H])CC1)C
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (121.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.2152 mL 6.0759 mL 12.1517 mL
    5 mM 0.2430 mL 1.2152 mL 2.4303 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (3.04 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (3.04 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.65%

    COA (256 KB) HNMR (329 KB) RP-HPLC (256 KB) LCMS (94 KB)

    Handling Instructions (2659 KB)
    References
    Animal Administration
    [3]

    Mice[3]
    NOD.H-2h4 mice are fed in the animal house until 4 weeks of age. A total of 24 male mice are then randomly separated into three different groups (n=8 per group). Mice in the control group are given sterile water without supplement. Mice in the iodine supplement (NaI) group are given 0.005% NaI in the drinking water. Mice in the NaI+Glycyrrhizic acid group are treated with 50 mg/kg Glycyrrhizic acid once daily for 4 weeks, administered via intraperitoneal injection after 8 weeks of iodine supplementation. Thyroid tissues are removed surgically under anesthesia, washed with cold saline, blotted on filter paper and weighed using an electronic balance. The thyroid gland tissues are then stored at -80°C until use[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.2152 mL 6.0759 mL 12.1517 mL 30.3793 mL
    5 mM 0.2430 mL 1.2152 mL 2.4303 mL 6.0759 mL
    10 mM 0.1215 mL 0.6076 mL 1.2152 mL 3.0379 mL
    15 mM 0.0810 mL 0.4051 mL 0.8101 mL 2.0253 mL
    20 mM 0.0608 mL 0.3038 mL 0.6076 mL 1.5190 mL
    25 mM 0.0486 mL 0.2430 mL 0.4861 mL 1.2152 mL
    30 mM 0.0405 mL 0.2025 mL 0.4051 mL 1.0126 mL
    40 mM 0.0304 mL 0.1519 mL 0.3038 mL 0.7595 mL
    50 mM 0.0243 mL 0.1215 mL 0.2430 mL 0.6076 mL
    60 mM 0.0203 mL 0.1013 mL 0.2025 mL 0.5063 mL
    80 mM 0.0152 mL 0.0759 mL 0.1519 mL 0.3797 mL
    100 mM 0.0122 mL 0.0608 mL 0.1215 mL 0.3038 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Glycyrrhizic acid Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Glycyrrhizic acid1405-86-3GlycyrrhizinVirus ProteaseInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Glycyrrhizic acid
    Cat. No.:
    HY-N0184
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.